Faricimab can reduce vascular leakage and inflammation in patients who demonstrated a poor response to other anti-VEGF agents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback